Key genetic drivers, including mutations in NF2, SMO, KLF4, TRAF7, and chromosomal aberrations, allow for the stratification of meningiomas into distinct molecular subtypes, each associated with unique clinical outcomes and therapeutic vulnerabilities [4,30,33,34,35,36]. Here, KLF4 is linked to meningioma.